Drug intelligence / Profile preview

UBX-106

Development stage: Unknown
Lead developer: Ubix Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

UBX-106 is a novel immuno-oncology therapeutic developed by Ubix Therapeutics. It is a proteolysis-targeting chimera (PROTAC) designed to degrade specific target proteins involved in cancer cell signaling. The drug specifically targets SHP2 (Src homology phosphotyrosyl phosphatase 2), a key regulator of the MAPK signaling pathway, which is implicated in various cancers. By promoting the degradation of SHP2, UBX-106 aims to disrupt oncogenic signaling and enhance anti-tumor immune responses. The drug leverages Ubix Therapeutics' proprietary Degraducer platform for targeted protein degradation[1][2][9].

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on UBX-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBX-106.

Explore the full profile